Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- EFPIA Japan Chief Frets Declining Priority for Japan Market since 2018 Pricing Overhaul
November 19, 2020
- Active Hep C Treatment Estimated to Save 1.3 Trillion Yen in Healthcare Costs in 20 Years: INES
November 18, 2020
- JPMA Sorts Out Challenges for Remote Clinical Trial to Promote Its Introduction in Japan
November 9, 2020
- Raise Copay Rates to 20% for Seniors Over 75 ASAP: 5 Insurers
November 5, 2020
- Sales Reps in Japan Decrease to 57,158 in FY2019, Down for 6 Years Running: Survey
November 5, 2020
- PhRMA Makes 3-Pronged Proposal to Japan Govt, Calls for Fueling Innovation, Investment, and Digitalization
October 29, 2020
- Japan Trade Groups Step Up Lobbying Campaigns as Diet Convenes, Renew Call for “Cautious Approach” to Off-Year Re-Pricing
October 27, 2020
- FPMAJ Urges Drug Makers to Ensure Stable Supply of Newly Listed Products
October 16, 2020
- COVID-19 Affecting Reimbursement Fee Incentive for Biosimilars: JPA Exec
October 16, 2020
- Take COVID as Opportunity to “Reset” Overdependence on Drug Price Cuts: PhRMA Chief
October 12, 2020
- Don’t Politicize Coronavirus Vaccine Introduction: Drug Damage Watchdog
October 8, 2020
- Ex-MHLW Official Takeyuki Sato Named JGA Director General
October 2, 2020
- Coronavirus Vaccines Must Be Offered to All Humanity: EFPIA Japan Webinar
October 1, 2020
- Generic Use Rate at 79.3% in April-June, Just Shy of Govt Target: JGA
October 1, 2020
- EFPIA Global, Japan Chiefs Call for Appropriate Reward for Innovation
September 30, 2020
- New Cabinet Well Organized, Full of People with Practical Experience: JPMA Director General
September 23, 2020
- Drug Wholesalers’ Sales Up 2.54%, Improving Profit Rates in FY2019: JPWA
September 23, 2020
- Ex-MHLW Councilor Mori to Become JPMA’s Sr. Managing Director in October
September 18, 2020
- Japan Pharma Groups Stepping Up Lobbying on FY2021 Budget, Tax Reform
September 17, 2020
- JPMA Policy Proposal Calls for Govt’s Flexibility towards Coronavirus Vaccinations, Steps to Expedite Visas for Foreign Technicians
September 15, 2020
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…